Daily Bulletin

Men's Weekly

.

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG-PR Newswire APAC

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG-PR Newswire APAC

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant...

Read more: US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG-PR...

Business News

The ultimate checklist for launching a digital-first business

If you’re launching a business in 2025, chances are it’s going to be digital-first. Whether you’re running an online store, offering consulting services, or building something entirely new, they all h...

Daily Bulletin - avatar Daily Bulletin

“SMBs Are Building the Future While Australia Sleeps” — Marc Degli on AI, Innovation, and What Needs to Change

Australia’s startup scene has been called “emerging” for a decade — but for many founders, it still feels stalled. Government funding is mired in bureaucracy. Investors hedge their bets on “safe” deal...

Daily Bulletin - avatar Daily Bulletin

Hydrogen Pipe Infrastructure: A Guide to Future Networks

As Australia moves towards a cleaner energy future, hydrogen is emerging as a key player. But how do we get this promising energy source from production facilities to where it's needed? The answer l...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals